Are Weight Loss Injections Safe? What the UK Data Actually Shows
Last updated: 8 August 2026
TL;DR: GLP-1 weight loss injections such as Mounjaro and Wegovy are licensed UK medicines with a well-characterised safety profile. Most side effects are gastrointestinal and mild to moderate. The MHRA has received suspected-death reports through its Yellow Card scheme, but a report signals suspicion, not proven cause, and the regulator states the benefits outweigh the risks when the medicines are used as authorised.
Weight loss injections in the GLP-1 class are prescription-only medicines regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). For most eligible patients under clinical supervision, the common side effects are digestive and settle over time. Serious harm is uncommon relative to how widely the medicines are prescribed, and large randomised trials have shown cardiovascular benefit in specific groups. The safety question is real and worth answering precisely, which is what this guide does.
What Did the "120 Deaths" Headline Actually Report?
The figure comes from the MHRA's Yellow Card scheme, which collects suspected reactions to medicines. According to MHRA Yellow Card data reported in August 2026, tirzepatide (the active ingredient in Mounjaro) had 106,189 suspected adverse reaction reports and 120 reports of a death that someone suspected might be linked. Semaglutide (Wegovy, Ozempic, Rybelsus) had 48,089 reaction reports and 59 suspected-death reports.
A Yellow Card report is a suspicion logged by a patient or clinician. It does not confirm the medicine caused the outcome. The MHRA has stated plainly that a report "did not necessarily mean that the death or the reaction was caused by the medicine." The headline number is a count of suspicions, not a count of confirmed drug-caused deaths, and reading it as the latter is the core error in the viral framing.
How Does the MHRA Track Suspected Side Effects?
The Yellow Card scheme is the UK's national system for reporting suspected problems with medicines, run by the MHRA. Anyone can submit a report: patients, carers, pharmacists, and doctors. The scheme is deliberately open, so it captures a wide net of suspicions that are then reviewed for genuine safety signals.
According to the BMJ (Iacobucci, 2025), UK data showed 82 deaths related to suspected adverse reactions to GLP-1 medicines by early 2025; the number rose through 2026 as prescribing grew. Rising report counts often track rising prescription volume and public awareness rather than rising per-patient risk. The MHRA makes this point directly: "It is important to place these reports in the context of the millions of GLP-1 prescriptions issued in the UK."
What Is the Difference Between a Reported and an Attributed Death?
A reported event is a suspected association; an attributed event is one where investigation establishes the medicine as a cause. The two are frequently conflated in coverage, which is how a spontaneous-reporting total becomes a "deaths caused by" headline. The distinction is the single most important thing to understand about GLP-1 safety data.
| Term | What it means | What it does not mean |
|---|---|---|
| Reported (Yellow Card) | Someone suspected a link and logged it | That the medicine caused the outcome |
| Serious report | The event met a seriousness threshold (e.g. hospitalisation) | That causation is proven |
| Attributed | Investigation established the medicine as a cause | Applies to the raw report count |
| Signal | A pattern the MHRA reviews for possible action | A confirmed risk on its own |
The MHRA reviews reports continuously and updates guidance when a genuine signal emerges. In January 2026 it updated product information for GLP-1 medicines to reflect a small risk of severe acute pancreatitis, and the Yellow Card Biobank, with Genomics England, is investigating whether genetics influence that pancreatitis risk. That is the system working as designed: suspicion, review, and proportionate action.
How Common Are Serious Side Effects on GLP-1 Medication?
Most side effects are gastrointestinal and mild to moderate, not life-threatening. According to a multidisciplinary expert consensus (Gorgojo Martínez et al., Journal of Clinical Medicine, 2022), the common effects, nausea, vomiting, diarrhoea and constipation, are typically transient, dose-dependent, and reduced by slow dose escalation. Of the more than 150,000 UK adverse reaction reports across GLP-1 brands, the majority concern these digestive effects.
Serious events are far less common but real, including acute pancreatitis and gallbladder problems, which is why prescriber screening and patient education matter. On benefit, the evidence is substantial: according to the SELECT trial (Lincoff et al., New England Journal of Medicine, 2023), semaglutide reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease. Safety is a balance of these risks and benefits, not a single number.
What Makes GLP-1 Treatment Safer or Riskier for a Patient?
The largest safety variable is the setting: a proper clinical assessment, a genuine prescriber, correct dosing, and monitoring. Risk rises sharply with unregulated or counterfeit supply, where dose and contents are unknown and no clinician is involved. The medicine is one factor; the pathway around it is often the larger one.
- Lowers risk: full eligibility and contraindication screening; slow dose titration; a named, contactable prescriber; honest reporting of symptoms.
- Raises risk: buying without a consultation; counterfeit or black-market products; hiding relevant medical history; ignoring red-flag symptoms.
Bolt Pharmacy operates as a GPhC-registered pharmacy with named prescribers and structured clinical review, which is the setting the safety evidence assumes. The regulator's overall position is unambiguous: on current evidence, the benefits of GLP-1 receptor agonists outweigh the potential risks when used in line with their authorised uses.
When Should Someone on Weight Loss Medication Seek Urgent Help?
Some symptoms need same-day medical attention rather than watchful waiting. Severe, persistent abdominal pain, especially pain radiating to the back with vomiting, can indicate pancreatitis and warrants urgent care. Signs of a severe allergic reaction, significant dehydration from prolonged vomiting, or symptoms of gallbladder problems also need prompt assessment.
Patients can and should report suspected reactions themselves through the MHRA Yellow Card portal, which feeds the same safety monitoring described above. For a fuller breakdown of which symptoms are expected and which are red flags, see the related guide below on GLP-1 warning signs.
Related Guides
- What Is the Yellow Card Scheme? How the UK Tracks Medication Side Effects
- GLP-1 Warning Signs: When Weight Loss Medication Side Effects Need Medical Attention
- How to Manage Common GLP-1 Side Effects: A Practical Patient Guide
- Who Should Not Take GLP-1 Weight Loss Medication? Contraindications Explained
- Counterfeit Weight Loss Jabs: Why the Source of Your Mounjaro Matters
Key Takeaways
- The MHRA Yellow Card death figures count suspected reports, not confirmed drug-caused deaths.
- Tirzepatide had 120 suspected-death reports against 106,189 reaction reports and millions of UK prescriptions in 2026.
- Most GLP-1 side effects are gastrointestinal, mild to moderate, and reduced by slow dose escalation.
- The SELECT trial showed a 20% reduction in major cardiovascular events with semaglutide in a high-risk group.
- Unregulated or counterfeit supply, not the licensed medicine used correctly, is the larger avoidable risk.
- The MHRA's position is that benefits outweigh risks when GLP-1 medicines are used as authorised.
Frequently Asked Questions
Are weight loss injections safe?
For eligible patients under clinical supervision, GLP-1 injections are licensed UK medicines with a well-characterised safety profile. Most side effects are digestive and settle over time. Serious events are uncommon relative to prescription volume, and the MHRA states the benefits outweigh the risks when used as authorised.
Did weight loss jabs really cause 120 deaths in the UK?
No. The 120 figure is the number of suspected-death reports for tirzepatide submitted to the MHRA Yellow Card scheme. A report reflects suspicion, not proven cause. The MHRA has stated a report does not mean the medicine caused the death.
What is the most common side effect of GLP-1 medication?
Nausea is the most commonly reported effect, alongside vomiting, diarrhoea and constipation. According to a 2022 expert consensus, these are usually mild to moderate, temporary, and reduced by escalating the dose slowly under clinical guidance.
When should I seek urgent help on a weight loss injection?
Seek same-day care for severe, persistent abdominal pain, especially with vomiting or pain spreading to the back, signs of a severe allergic reaction, or significant dehydration. These can indicate serious problems such as pancreatitis and should not be monitored at home.
Published by Bolt Pharmacy, a GPhC-registered UK pharmacy. Sources: MHRA Yellow Card scheme data and guidance (2025–2026); Lincoff et al., New England Journal of Medicine (2023); Iacobucci, BMJ (2025;388:r390); Gorgojo Martínez et al., Journal of Clinical Medicine (2022). This guide is educational and does not replace advice from a healthcare professional. Figures reflect published data as of August 2026 and may change.
